Inicio > Cardiología > Recientes aportes al síndrome coronario agudo > Página 4

Recientes aportes al síndrome coronario agudo

Referencias bibliográficas

  1. Thygesen K, Alpert JS, Jaffe AS. Third universal definition of myocardial infarction. Circulation 2012;126:2020–35.
  2. Baron T, Hambraeus K, Sundstrom J. Type 2 myocardial infarction in clinical practice. Heart 2015;101:101–6.
  3. Saaby L, Poulsen TS, Diederichsen AC. Mortality rate in type 2 myocardial infarction: observations from an unselected hospital cohort. Am J Med 2014;127:295–302.
  4. O’Gara PT, Kushner FG, Ascheim DD. 2013 ACCF/AHA guideline for the management of ST elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78–e140.
  5. Go AS, Mozaffarian D, Roger VL. Heart disease and stroke statistics—2013 update: A report from the American Heart Association. Circulation 2013;127:e6–e245.
  6. Anuario estadístico de salud. Cuba 2014. Ministerio de salud pública. Dirección de registros médicos y de estadísticas de salud. La Habana. Cuba [Internet] 2015. [Citado dic 2015] pp 31-4 : Disponible en
  7. Body R, Carley S, Wibberley C. The value of symptoms and signs in the emergent diagnosis of acute coronary syndromes. Resuscitation 2010;81:281–6.
  1. Boubaker H. Habib M. Beltaief K. Haj Amor M. Mdimagh Z. Boukhris A. et al. A New Score for the Diagnosis of Acute Coronary Syndrome in Acute Chest Pain With Non-diagnostic ECG and Normal Troponin. Emerg Med J. 2015;32(10):764-8.
  2. Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Zieman, S. J. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Col Cardiol 2014; 64(24): e139-e228.
  3. Anderson JL, Heidenreich PA, Barnett PG. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63: 2304-22.
  4. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiologic update. Eur Heart J 2013;34: 3028–34.
  5. Gillespie CD, Wigington C, Hong Y; Centers for Disease Control and Prevention (CDC). Coronary heart disease and stroke deaths – United States, 2009.MMWR Surveill Summ 2013; 62(Suppl. 3):157–60.
  6. Angeloni E, Paneni F, Landmesser U, Benedetto U, Melina G, Lüscher et al. Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J 2013; 34: 3557–62.
  7. Silbernagel G, Schöttker B, Appelbaum S, Scharnagl H, Kleber ME, Grammer TB, et al. High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality. Eur Heart J 2013;34: 3563–71.
  8. Wright RS, Anderson JL, Adams CD. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123: e426–579.
  9. Smith, J N. Negrelli, J M. Manek, M B. Hawes, E H. Viera, A J. Diagnosis and Management of Acute Coronary Syndrome: An Evidence-based Update. J Am Board Fam Med. 2015; 28(2):283-93.
  10. Navarese EP, Gurbel PA, Andreotti F. Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: A systematic review and meta-analysis. Ann Intern Med 2013;158: 261–70.
  11. Jneid H, Anderson JL, Wright RS. 2012 ACCF/AHA focused update of the guideline for the management of unstable angina/non-ST segment myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol. 2012; 60: 645–81.
  12. Montalescot G, Sechtem U, Achenbach S, Andreotti F. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J2013; 34: 2949–3003. doi: 10.1093/eurheartj/eht296. pmid:23996286
  1. Chmiel C, Reich O, Signorell A, Tandjung R, Rosemann T, Senn O. Appropriateness of Diagnostic Coronary Angiography as a Measure of Cardiac Ischemia Testing in Non-Emergency Patients – A Retrospective Cross-Sectional Analysis. PLoS ONE 2015;10(2): e0117-172. doi:10.1371/journal.pone.0117172
  2. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012;126: 3097–137. doi: 10.1161/CIR.0b013e3182776f83. pmid:23166210
  3. David Doron, C. Marcelo Muñoz. Marcadores cardiacos y riesgo cardiovascular. Rev Méd Clíni Las Condes 2015;26(2):133-41
  4. Lahoz-Tornos, Á., Vilchez-Aguilera, J. A., Hernandez-Romero, D., Romero-Aniorte, A. I., Orenes-Piñero, E., Jara-Rubio, R. Marín-Ortuño, F.Colesterol HDL y troponina T ultrasensible como biomarcadores predictivos de fibrilación auricular postoperatoria. Arch card Méx 2015; 8(2:):111-7.
  5. Skinner JS, Smeeth L, Kendall JM, Adams PC, Timmis A. NICE guidance. Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin. Heart 2010; 96: 974–8. doi: 10.1136/hrt.2009.190066. pmid:20538674
  6. Cheng VY, Berman DS, Rozanski A, Dunning AM, Achenbach S. Performance of the traditional age, sex, and angina typicality-based approach for estimating pretest probability of angiographically significant coronary artery disease in patients undergoing coronary computed tomographic angiography: results from the multinational coronary CT angiography evaluation for clinical outcomes: an international multicenter registry (CONFIRM). Circulation 2011;124: 2423–32
  1. Cheng JW. Updates in antiplatelet agents used in cardiovascular diseases. J Cardiovasc Pharmacol Ther 2013; 18: 514–24.
  2. Mehta SR, Tanguay JF, Eikelboom JW. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENTOASIS 7): A randomised factorial trial. Lancet 2010;376: 1233–43.
  3. Arredondo Bruce AE, Acuña Sobrino, J E. Arredondo Rubido AE. Dosificación de la aspirina en el síndrome coronario agudo. Revmedicaelectronica.2015;37(4):364-73
  4. O’Brien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR, et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2014;167(4):601-9
  5. Kohli P, Udell J, Murphy S, Cannon CP, Antman EM, Braunwald E, et al. Discharge aspirin dose and clinical outcomes in patients with ACS: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). J Am Coll Cardiol. 2014; 63(3):225-332.
  6. Yusuf S, Zhao F, Mehta SR. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494 –502.
  7. Wiviott SD, Braunwald E, McCabe CH. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15
  8. Morrow DA, Braunwald E, Bonaca MP. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012;366: 1404–13.
  9. Ganetsky VS, Hadley DE, Thomas TF. Role of Novel and Emerging Oral Anticoagulants for Secondary Prevention of Acute Coronary Syndromes. Pharmacotherapy. 2014;34: 590–604.
  10. Kezerashvili A, Marzo K, De Leon J. Beta blocker use after acute myocardial infarction in the patient with normal systolic function: When is it «ok» to discontinue? Curr Cardiol Rev. 2012;8: 77–84.
  11. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889 –934.